세계의 복합주사제 시장 보고서(2025년)

Complex injectables refer to advanced pharmaceutical products that require sophisticated formulation and sterile manufacturing processes for injection. They are used to deliver targeted therapies, vaccines, or biologics directly into the body, addressing diseases that cannot be effectively treated with conventional oral medications.

The primary product types of complex injectables include monoclonal antibodies, gene therapies, vaccines, proteins and peptides, and antibody-drug conjugates (ADCs). Monoclonal antibodies are laboratory-produced molecules that mimic the immune system's ability to recognize and bind specific antigens. They are applied across therapeutic areas such as oncology, diabetes, autoimmune disorders, neurological disorders, cardiovascular diseases, and infectious diseases. Routes of administration include intravenous (IV), subcutaneous (SC), intramuscular (IM), epidural, and intradermal. Distribution occurs through direct sales, pharmacies, e-commerce platforms, distributors, and wholesalers. Key end users include hospitals, ambulatory surgical centers, specialty clinics, home healthcare providers, and research institutions.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the pharmaceutical companies contend with tariffs on APIs, glass vials, and lab equipment inputs with few alternative sources. Generic drug makers, operating on razor-thin margins, are especially vulnerable, with some reducing production of low-profit medicines. Biotech firms face delays in clinical trials due to tariff-related shortages of specialized reagents. In response, the industry is expanding API production in India and Europe, increasing inventory stockpiles, and pushing for trade exemptions for essential medicines.

The complex injectable market research report is one of a series of new reports from The Business Research Company that provides complex injectable market statistics, including the complex injectable industry global market size, regional shares, competitors with the complex injectable market share, detailed complex injectable market segments, market trends, and opportunities, and any further data you may need to thrive in the complex injectable industry. This complex injectable market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The complex injectable market size has grown rapidly in recent years. It will grow from $17.70 billion in 2024 to $19.77 billion in 2025 at a compound annual growth rate (CAGR) of 11.7%. The growth during the historic period is linked to increasing prevalence of chronic diseases, rising demand for targeted biologic therapies, growing adoption of self-administration devices, expanding applications in oncology, and higher regulatory approvals for biosimilars.

The complex injectable market size is expected to see rapid growth in the next few years. It will grow to $30.38 billion in 2029 at a compound annual growth rate (CAGR) of 11.3%. The growth projected for the forecast period is driven by growing focus on personalized medicine, increasing healthcare expenditure, expanding applications in autoimmune disorders, rising patient preference for minimally invasive treatments, and higher demand for self-administration devices. Primary trends during the forecast period include advancements in biologic therapies, technological innovations in drug delivery systems, developments in nanotechnology for targeted delivery, improvements in cold chain logistics, and progress in injectable peptide and protein therapeutics.

The rising prevalence of chronic diseases is expected to drive growth in the complex injectable market in the coming years. Chronic diseases are long-term medical conditions that generally progress slowly and require continuous management. Factors such as aging populations contribute to this increase, as older adults are more prone to conditions such as diabetes, heart disease, and arthritis. Complex injectables aid in managing these chronic illnesses by delivering targeted medications that help control symptoms and slow disease progression. For example, the Office for Health Improvement & Disparities (OHID), a UK-based public health agency, projects that the global number of adults living with diabetes will increase from 537 million in 2021 to 643 million by 2030. Thus, the growing burden of chronic diseases is driving demand in the complex injectable market.

Leading companies in drug delivery systems are focusing on innovations such as autoinjector dosage forms to improve patient convenience, enhance treatment adherence, ensure precise and safe drug administration, and facilitate effective delivery of complex biologic therapies. Autoinjectors are pre-filled, self-administered injection devices designed to safely and accurately deliver a specific medication dose, often used for biologics and other complex drugs. For instance, in January 2024, Taisho Pharmaceutical Co. Ltd., a Japan-based generic drug manufacturer, launched Nanozora 30 mg for subcutaneous injection. This patient-friendly device allows for easy self-administration and includes a needle-covering feature to prevent accidental needle sticks. It enables patients with rheumatoid arthritis to conveniently receive treatment once every four weeks, broadening Taisho's treatment options beyond its existing syringe formulations.

In April 2024, Eli Lilly and Company, a US-based pharmaceutical giant, acquired Nexus Pharmaceuticals Inc. for an undisclosed sum. This acquisition expands Lilly's parenteral (injectable) manufacturing capabilities by incorporating Nexus's advanced sterile manufacturing facility. The move strengthens Lilly's ability to meet increasing demand for complex injectable drugs and supports its robust pipeline targeting conditions such as diabetes, obesity, and migraine. Nexus Pharmaceuticals Inc. is a US-based firm specializing in the development and production of generic and specialty injectable medications.

Major players in the complex injectable market are Johnson & Johnson Pharmaceutical, Merck & Co. Inc., Pfizer Inc., Bayer AG, Novartis AG, Bristol-Myers Squibb Company, Novo Nordisk, Takeda Pharmaceutical Company Limited, Amgen Inc., Boehringer Ingelheim GmbH, Baxter Healthcare Corporation, Fresenius Kabi, Sun Pharmaceutical Industries Ltd., Hikma Pharmaceuticals, Indivior PLC, Amphastar Pharmaceuticals Inc., Braun Melsungen AG, Ferring Pharmaceuticals, Oakwood Labs, ForDoz Pharma.

North America was the largest region in the complex injectable market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in complex injectable report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the complex injectable market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The complex injectable market consists of sales of liposomal injections, depot injections, nanoparticle-based injectables, emulsions, and suspensions. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Complex Injectable Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on complex injectable market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for complex injectable ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The complex injectable market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Product Type: Monoclonal Antibodies; Gene Therapies; Vaccines Proteins and Peptides; Antibody-Drug Conjugates (ADCs)
• 2) By Therapeutic Area: Oncology; Diabetes; Autoimmune Disorders; Neurological Disorders; Cardiovascular Diseases; Infectious Diseases
• 3) By Route of Administration: Intravenous (IV); Subcutaneous (SC); Intramuscular (IM); Epidural; Intradermal
• 4) By Distribution Channel: Direct Sale; Pharmacies; eCommerce; Distributors; Wholesalers
• 5) By End User: Hospitals; Ambulatory Surgical Centers; Specialty Clinics; Home Healthcare; Research Institutions
• Subsegments:
• 1) By Monoclonal Antibodies: Chimeric Monoclonal Antibodies; Humanized Monoclonal Antibodies; Fully Human Monoclonal Antibodies; Bispecific Monoclonal Antibodies
• 2) By Gene Therapies: Somatic Gene Therapy; Germline Gene Therapy; Ex Vivo Gene Therapy; In Vivo Gene Therapy
• 3) By Vaccines, Proteins And Peptides: Recombinant Proteins; Synthetic Peptides; mRNA Vaccines; Viral Vector Vaccines
• 4) By Antibody Drug Conjugates: Cleavable Linker Antibody Drug Conjugates; Non-cleavable Linker Antibody Drug Conjugates; Cytotoxic Payload Antibody Drug Conjugates; Target-specific Antibody Drug Conjugates
• Companies Mentioned: Johnson & Johnson Pharmaceutical; Merck & Co. Inc.; Pfizer Inc.; Bayer AG; Novartis AG; Bristol-Myers Squibb Company; Novo Nordisk; Takeda Pharmaceutical Company Limited; Amgen Inc.; Boehringer Ingelheim GmbH; Baxter Healthcare Corporation; Fresenius Kabi; Sun Pharmaceutical Industries Ltd.; Hikma Pharmaceuticals; Indivior PLC; Amphastar Pharmaceuticals Inc.; Braun Melsungen AG; Ferring Pharmaceuticals; Oakwood Labs; ForDoz Pharma
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Complex Injectable Market Characteristics

3. Complex Injectable Market Trends And Strategies

4. Complex Injectable Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

• 4.1. Supply Chain Impact from Tariff War & Trade Protectionism

5. Global Complex Injectable Growth Analysis And Strategic Analysis Framework

• 5.1. Global Complex Injectable PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Complex Injectable Market Growth Rate Analysis
• 5.4. Global Complex Injectable Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Complex Injectable Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Complex Injectable Total Addressable Market (TAM)

6. Complex Injectable Market Segmentation

• 6.1. Global Complex Injectable Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Monoclonal Antibodies
• Gene Therapies
• Vaccines Proteins and Peptides
• Antibody-Drug Conjugates (ADCs)
• 6.2. Global Complex Injectable Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oncology
• Diabetes
• Autoimmune Disorders
• Neurological Disorders
• Cardiovascular Diseases
• Infectious Diseases
• 6.3. Global Complex Injectable Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Intravenous (IV)
• Subcutaneous (SC)
• Intramuscular (IM)
• Epidural
• Intradermal
• 6.4. Global Complex Injectable Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Direct Sale
• Pharmacies
• eCommerce
• Distributors
• Wholesalers
• 6.5. Global Complex Injectable Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Ambulatory Surgical Centers
• Specialty Clinics
• Home Healthcare
• Research Institutions
• 6.6. Global Complex Injectable Market, Sub-Segmentation Of Monoclonal Antibodies, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Chimeric Monoclonal Antibodies
• Humanized Monoclonal Antibodies
• Fully Human Monoclonal Antibodies
• Bispecific Monoclonal Antibodies
• 6.7. Global Complex Injectable Market, Sub-Segmentation Of Gene Therapies, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Somatic Gene Therapy
• Germline Gene Therapy
• Ex Vivo Gene Therapy
• In Vivo Gene Therapy
• 6.8. Global Complex Injectable Market, Sub-Segmentation Of Vaccines, Proteins & Peptides, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Recombinant Proteins
• Synthetic Peptides
• mRNA Vaccines
• Viral Vector Vaccines
• Protein Subunit Vaccines
• 6.9. Global Complex Injectable Market, Sub-Segmentation Of Antibody Drug Conjugates, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Cleavable Linker Antibody Drug Conjugates
• Non Cleavable Linker Antibody Drug Conjugates
• Cytotoxic Payload Antibody Drug Conjugates
• Target Specific Antibody Drug Conjugates

7. Complex Injectable Market Regional And Country Analysis

• 7.1. Global Complex Injectable Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Complex Injectable Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Complex Injectable Market

• 8.1. Asia-Pacific Complex Injectable Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Complex Injectable Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Complex Injectable Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Complex Injectable Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Complex Injectable Market

• 9.1. China Complex Injectable Market Overview
• 9.2. China Complex Injectable Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Complex Injectable Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Complex Injectable Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Complex Injectable Market

• 10.1. India Complex Injectable Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Complex Injectable Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Complex Injectable Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Complex Injectable Market

• 11.1. Japan Complex Injectable Market Overview
• 11.2. Japan Complex Injectable Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Complex Injectable Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Complex Injectable Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Complex Injectable Market

• 12.1. Australia Complex Injectable Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Complex Injectable Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Complex Injectable Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Complex Injectable Market

• 13.1. Indonesia Complex Injectable Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Complex Injectable Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Complex Injectable Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Complex Injectable Market

• 14.1. South Korea Complex Injectable Market Overview
• 14.2. South Korea Complex Injectable Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Complex Injectable Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Complex Injectable Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Complex Injectable Market

• 15.1. Western Europe Complex Injectable Market Overview
• 15.2. Western Europe Complex Injectable Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Complex Injectable Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Complex Injectable Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Complex Injectable Market

• 16.1. UK Complex Injectable Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Complex Injectable Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Complex Injectable Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Complex Injectable Market

• 17.1. Germany Complex Injectable Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Complex Injectable Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Complex Injectable Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Complex Injectable Market

• 18.1. France Complex Injectable Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Complex Injectable Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Complex Injectable Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Complex Injectable Market

• 19.1. Italy Complex Injectable Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Complex Injectable Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Complex Injectable Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Complex Injectable Market

• 20.1. Spain Complex Injectable Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Complex Injectable Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Complex Injectable Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Complex Injectable Market

• 21.1. Eastern Europe Complex Injectable Market Overview
• 21.2. Eastern Europe Complex Injectable Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Complex Injectable Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Complex Injectable Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Complex Injectable Market

• 22.1. Russia Complex Injectable Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Complex Injectable Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Complex Injectable Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Complex Injectable Market

• 23.1. North America Complex Injectable Market Overview
• 23.2. North America Complex Injectable Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Complex Injectable Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Complex Injectable Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Complex Injectable Market

• 24.1. USA Complex Injectable Market Overview
• 24.2. USA Complex Injectable Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Complex Injectable Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Complex Injectable Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Complex Injectable Market

• 25.1. Canada Complex Injectable Market Overview
• 25.2. Canada Complex Injectable Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Complex Injectable Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Complex Injectable Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Complex Injectable Market

• 26.1. South America Complex Injectable Market Overview
• 26.2. South America Complex Injectable Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Complex Injectable Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Complex Injectable Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Complex Injectable Market

• 27.1. Brazil Complex Injectable Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Complex Injectable Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Complex Injectable Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Complex Injectable Market

• 28.1. Middle East Complex Injectable Market Overview
• 28.2. Middle East Complex Injectable Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Complex Injectable Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Complex Injectable Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Complex Injectable Market

• 29.1. Africa Complex Injectable Market Overview
• 29.2. Africa Complex Injectable Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Complex Injectable Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Complex Injectable Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Complex Injectable Market Competitive Landscape And Company Profiles

• 30.1. Complex Injectable Market Competitive Landscape
• 30.2. Complex Injectable Market Company Profiles
  • 30.2.1. Johnson & Johnson Pharmaceutical Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Bayer AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Novartis AG Overview, Products and Services, Strategy and Financial Analysis

31. Complex Injectable Market Other Major And Innovative Companies

• 31.1. Bristol-Myers Squibb Company
• 31.2. Novo Nordisk
• 31.3. Takeda Pharmaceutical Company Limited
• 31.4. Amgen Inc.
• 31.5. Boehringer Ingelheim GmbH
• 31.6. Baxter Healthcare Corporation
• 31.7. Fresenius Kabi
• 31.8. Sun Pharmaceutical Industries Ltd.
• 31.9. Hikma Pharmaceuticals
• 31.10. Indivior PLC
• 31.11. Amphastar Pharmaceuticals Inc.
• 31.12. Braun Melsungen AG
• 31.13. Ferring Pharmaceuticals
• 31.14. Oakwood Labs
• 31.15. ForDoz Pharma

32. Global Complex Injectable Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Complex Injectable Market

34. Recent Developments In The Complex Injectable Market

35. Complex Injectable Market High Potential Countries, Segments and Strategies

• 35.1 Complex Injectable Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Complex Injectable Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Complex Injectable Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer